Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction

Iwona Swiatkiewicz · Marek Kozinski · Przemyslaw Magielski · Joanna Gierach · Tomasz Fabiszak · Aldona Kubica · Adam Sukiennik · Eliano Pio Navarese · Grazyna Odrowaz-Sypniewska · Jacek Kubica

Abstract

Objective To assess the usefulness of in-hospital measurement of C-reactive protein (CRP) concentration in comparison to well-established risk factors as a marker of post-infarct left ventricular systolic dysfunction (LVSD) at discharge.

Materials and methods Two hundred and four consecutive patients with ST-segment-elevation myocardial infarction (STEMI) were prospectively enrolled into the study. CRP plasma concentrations were measured before reperfusion, 24 h after admission and at discharge with an ultra-sensitive latex immunoassay.

Results CRP concentration increased significantly during the first 24 h of hospitalization (2.4 ± 1.9 vs. 15.7 ± 17.0 mg/L; p < 0.001) and persisted elevated at discharge (14.7 ± 14.7 mg/L), mainly in 57 patients with LVSD (2.4 ± 1.8 vs. 25.0 ± 23.4 mg/L; p < 0.001; CRP at discharge 21.9 ± 18.6 mg/L). The prevalence of LVSD was significantly increased across increasing tertiles of CRP concentration both at 24 h after admission (13.2 vs. 19.1 vs. 51.5 %; p < 0.0001) and at discharge (14.7 vs. 23.5 vs. 45.6 %; p < 0.0001). Multivariate analysis demonstrated CRP concentration at discharge to be an independent marker of early LVSD (odds ratio of 1.38 for a 10 mg/L increase, 95 % confidence interval 1.01–1.87; p < 0.04).

Conclusion Measurement of CRP plasma concentration at discharge may be useful as a marker of early LVSD in patients after a first STEMI.

Keywords Acute myocardial infarction · Left ventricular function · Echocardiography · C-reactive protein · Inflammation

Introduction

Post-infarct left ventricular systolic dysfunction (LVSD) has been identified as a powerful marker of poor prognosis. Its occurrence is associated with an increased risk of cardiac death, re-infarction and re-hospitalization [1–4]. Furthermore, half of patients diagnosed with early post-infarct LVSD subsequently develop chronic heart failure. The prevalence of post-infarct LVSD ranges from 27 to 60 %, depending on the diagnostic criteria applied, therapeutic approach and time when the assessment is made [1–4].

Acute myocardial infarction (MI) provokes a systemic inflammatory response with a release of pro-inflammatory cytokines and enhanced synthesis of C-reactive protein (CRP) [5]. The triggers of cytokine and growth factor release in the setting of MI include mechanical deformation of left ventricle, ischaemia with necrosis, generation of reactive oxygen species, and cytokine self-amplification pathways [6]. Those mediators affect necrosis expansion...
and scar formation as well as stimulate CRP expression [7].
An increase in CRP plasma concentration in the course of acute MI begins in the first hours following the onset of symptoms, peaks approximately on day 2, and returns to its baseline value after a few weeks [8].

An accumulating body of evidence indicates a close relationship between increased CRP concentrations in patients with MI and excessive mortality in the medium- and long-term follow-up [9–13]. Additionally, evaluation of CRP concentration in this population provides prognostic information independent from the classical risk factors and enhances the value of well-established risk scores [14]. However, the link between CRP and structural and functional cardiac alterations in STEMI patients warrants further investigation.

We therefore set out to assess the usefulness of in-hospital measurement of CRP plasma concentration in comparison to well-established clinical, biochemical and angiographic risk factors as a marker of post-infarct LVSD at discharge in patients with a first ST-segment-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).

Materials and methods

Study design and patient characteristics

This study was designed as a single-center prospective observational cohort trial in the setting of first STEMI treated with pPCI. Two hundred and four consecutive patients (156 men and 48 women) meeting the study inclusion and exclusion criteria were enrolled.

The inclusion criteria were as follows: (1) typical stenocardial chest pain of at least 30 min duration, (2) onset of symptoms <12 h before hospital admission and (3) electrocardiographic features of acute STEMI (ST-segment elevation ≥0.1 mV or ≥0.2 mV in at least two continuous limb or precordial leads, respectively).

The exclusion criteria were: (1) prior coronary revascularization, (2) cardiogenic shock on admission, (3) heart failure (class III or IV according to the New York Heart Association classification), (4) bundle branch block, (5) permanent atrial fibrillation, (6) hemodynamically significant valvular heart disease, (7) primary cardiomyopathy, (8) severe arterial hypertension, (9) creatinine concentration >176.8 mmol/L, (10) the presence of features suggestive of an active inflammatory or neoplastic process on admission, and (11) therapy with steroids, immunosuppressive agents and non-steroidal anti-inflammatory drugs (excluding low doses of aspirin).

The study endpoint was global LVSD, the echocardiographic criterion for which was defined based on previous studies as left ventricular ejection fraction (LVEF) ≤40 % [2, 15, 16]. The patients were divided according to the values of LVEF at discharge into the subgroups with (LVEF ≤40 %) and without (LVEF >40 %) LVSD.

Approval from the local Bioethics Committee at Collegium Medicum in Bydgoszcz was obtained. All patients gave their written, voluntary, informed consent for participation in the study.

Pharmacotherapy

At the first contact with health care providers immediately after the diagnosis of STEMI, all patients were pre-treated with an intravenous bolus of unfractionated heparin (70 IU/kg, up to 5,000 IU) and oral loading doses of clopidogrel (600 mg) and aspirin (300 mg). At the catheterization laboratory a second dose of unfractionated heparin was administered intra-arterially in a weight-adjusted manner (up to 100 IU/kg) or under activated clotting time guidance (to the target range of 200–250 s) when abciximab was intended. Abciximab was given at the discretion of the invasive cardiologist. Throughout the study period clopidogrel and aspirin 75 mg q.d. were continued in all patients. Concomitant medications in the majority of patients included perindopril and long-acting metoprolol in doses adjusted for resting heart rate and blood pressure, and simvastatin 40 mg q.d. (Table 1). Additionally, 17 (8.3 %) patients were treated with spironolactone while 13 (6.4 %) participants received non-potassium-sparing diuretics.

Coronary angiography and pPCI

Coronarography and pPCI were performed using a standard femoral approach. The use of aspiration thrombectomy during the intervention was left to the operator’s discretion. Intracoronary stents were routinely implanted. Coronary artery stenosis was measured with quantitative coronary angiography. Epicardial coronary flow was assessed according to the TIMI Myocardial Infarction (TIMI) score and TIMI Frame Count (TFC), and myocardial perfusion according to the TIMI Myocardial Perfusion Grade (TMPG).

Echocardiography

Transthoracic echocardiographic recordings employing the Doppler technique were acquired before discharge using a Philips SONOS 7500 Ultrasound System, according to the protocol recommended by the American Society of Echocardiography [17]. Echocardiographic recordings were assessed offline by two independent experienced echocardiographers blinded to the values of biomarker measurement. Measurements are reported as the average of
three consecutive cardiac cycles. The echocardiographic results obtained by echocardiographers were averaged. The inter- and intra-observer coefficients of variation for LVEF assessed in the first 50 patients were below 5.0 and 2.5 %, respectively.

We assessed the sizes of the heart chambers, myocardium wall thickness and the following parameters of left ventricular systolic function: (1) LVEF measured with the biplane method of discs in four- and two-chamber views, and (2) wall motion score index (WMSI), derived as a sum of all scores divided by the number of segments visualized, implementing the 16-segment model of left ventricle segmentation and assigning a score of 1, 2, 3, or 4 points for normokinesis, hypokinesis, akinesis and dyskinesis, respectively [18]. Left ventricular mass was calculated according to the Devereux formula [19]. Measurements of peak systolic mitral annular velocities were obtained for four basal segments of the left ventricle (septal, lateral, inferior and anterior) using pulsed tissue Doppler echocardiography with the Doppler gate targeted at the junction between the left ventricle walls and the mitral annulus in four- and two-chamber views. The average peak systolic mitral annular velocity ($S'$) and an average septal and lateral peak systolic mitral annular velocity ($S''$) were obtained.

Blood sampling and laboratory analyses

Peripheral venous blood samples were collected using ethylenediaminetetraacetic acid tubes. After being centrifuged, the plasma was stored at $-80 \, ^\circ C$ until analyzed.

CRP plasma concentrations were measured with an ultra-sensitive latex immunoassay (CRP Vario test, analyzer: ARCHITECT ci8200, Abbott) at admission, 24 h after admission and at discharge. B-type natriuretic peptide (BNP) plasma concentration was measured with a chemiluminescent microparticle immunoassay (analyzer: ARCHITECT ci8200) at admission and at discharge. The limits of detection for CRP and BNP were 0.1 mg/L and 10 pg/L, respectively. The intra-assay coefficients of variation were below 2.0 % for CRP and below 5.0 % for BNP, while the inter-assay coefficients of variation were

| Variable | Overall study population ($n = 204$) | Patients with LVSD ($n = 57$) | Patients without LVSD ($n = 147$) | $p$ for comparison between groups with and without LVSD |
|----------|------------------------------------|-------------------------------|-----------------------------------|---------------------------------------------|
| Age (years) | 57.0 ± 9.2 | 59.0 ± 8.7 | 56.2 ± 9.3 | <0.05 |
| Gender (male/female), n (%) | 156/48 (76.5/23.5) | 43/14 (75.4/24.6) | 113/34 (76.9/23.1) | NS |
| Anterior wall STEMI, n (%) | 89 (43.6) | 52 (91.2) | 37 (25.2) | <0.001 |
| Time from onset of pain to balloon (min) | 238.2 ± 151.1 | 233.8 ± 150.0 | 244.9 ± 150.8 | NS |
| Risk factors for coronary artery disease | | | | |
| Body mass index (kg/m²) | 26.8 ± 3.9 | 27.9 ± 4.3 | 26.4 ± 3.6 | <0.01 |
| Hypertension, n (%) | 84 (41.2) | 31 (54.4) | 53 (36.1) | <0.02 |
| Diabetes mellitus, n (%) | 37 (18.1) | 15 (26.3) | 22 (15.0) | NS |
| Current or ex-smoker, n (%) | 134 (65.7) | 34 (59.7) | 100 (68.0) | NS |
| LDL cholesterol (mmol/L) | 3.87 ± 1.02 | 3.92 ± 1.09 | 3.85 ± 1.0 | NS |
| HDL cholesterol (mmol/L) | 1.37 ± 0.29 | 1.27 ± 0.26 | 1.38 ± 0.29 | <0.05 |
| Triglycerides (mmol/L) | 1.33 ± 1.08 | 1.41 ± 0.86 | 1.30 ± 1.15 | <0.05 |
| Cardiological history | | | | |
| Angina proceeding to myocardial infarction, n (%) | 86 (42.2 %) | 26 (45.6 %) | 60 (40.8 %) | NS |
| Heart failure prior to MI (I or II class according to the NYHA classification), n (%) | 7 (3.5) | 3 (5.3) | 4 (2.7) | NS |
| Medical treatment | | | | |
| Long-acting metoprolol | 202 (99.0 %) | 56 (98.2 %) | 146 (99.3 %) | NS |
| Perindopril | 200 (98.0 %) | 55 (96.5 %) | 145 (98.6 %) | NS |
| Simvastatin | 203 (99.5 %) | 57 (100.0 %) | 146 (99.3 %) | NS |
| Spironolactone | 17 (8.3 %) | 10 (17.5 %) | 7 (4.8 %) | <0.004 |
| Non-potassium-sparing diuretics | 13 (6.4 %) | 8 (14.0 %) | 5 (3.4 %) | <0.006 |

LVSD left ventricular systolic dysfunction, MI myocardial infarction, NYHA New York Heart Association, STEMI ST-segment-elevation myocardial infarction
compared using the sons within the groups. Categorical variables were matched-paired rank sum test were applied for comparison. Multivariate analyses.

Obtain such high power to be able to perform credible admission and at discharge, respectively. We decided to between patients with and without LVSD at 24 h after demonstration significant differences in CRP concentrations of 200 patients would provide a 99.9 and 98.9 % power to two-sided alpha value of 0.05, we calculated that enrolment t RVSD along with reductions in mean CRP values in STEMI patients in recent years, we decided to perform an internal pilot study of the first 50 patients for estimating the final sample size. To compensate for the potential loss of patients due to withdrawal of consent or other reasons, we enrolled an additional patient. LVSD was present in 15 (29.4 %) subjects. CRP concentrations in the first 51 patients assessed for the overall population and for patients with and without LVSD were, respectively (1) on admission 2.6 ± 2.1, 2.7 ± 1.9 and 2.6 ± 2.1 mg/L, (2) at 24 h after admission 15.8 ± 14.1, 25.6 ± 19.0 and 11.7 ± 9.7 mg/L, and (3) at discharge 16.5 ± 16.2, 24.0 ± 19.9 and 13.4 ± 13.5 mg/L. Based on these results and assuming a two-sided alpha value of 0.05, we calculated that enrolment of 200 patients would provide a 99.9 and 98.9 % power to demonstrate significant differences in CRP concentrations between patients with and without LVSD at 24 h after admission and at discharge, respectively. We decided to obtain such high power to be able to perform credible multivariate analyses.

Continuous variables were presented as mean values ± standard deviations. The Shapiro–Wilk test was used to demonstrate whether the investigated variables were normally distributed. Depending on the presence or absence of normal distribution, inter-group comparisons were performed with Student’s t test for independent samples or the Mann–Whitney unpaired rank sum test, whereas Student’s t test for paired samples or the Wilcoxon matched-paired rank sum test were applied for comparisons within the groups. Categorical variables were compared using the χ² test with Yates’ correction if needed.

Univariate and multivariate logistic regression models were used to identify markers of LVSD. Relations between the investigated variables and the likelihood of LVSD were estimated with the use of odds ratios (ORs) and their 95 % confidence intervals (95 % CIs). The optimal cut-off points were determined using receiver operator characteristic (ROC) curve analysis.

The impact of numerous variables on a quantitative variable was assessed using the multiple regression model. A two-sided difference was considered significant at p < 0.05. The statistical analysis and sample size calculation were carried out using the Statistica 10.0 package (StatSoft, Tulsa, OK, USA).

Results

Clinical, echocardiographic and angiographic assessment

LVSD at discharge was present in 57 (27.9 %) patients in our study. Patients with LVSD when compared to those with LVEF >40 % were older, had much more frequent anterior location of STEMI, and were more likely to be overweight, dyslipidemic and hypertensive (Table 1).

The subgroup with LVEF ≤40 % had significantly higher diameters of left atrium and left ventricle, bigger systolic and diastolic left ventricular volumes and greater left ventricle mass than patients with LVEF >40 % (Table 2). Similarly, in the former group we observed significantly higher values of WMSI and markedly lower average peak systolic mitral annular velocity and average septal and lateral peak systolic mitral annulus velocity indicating more impaired regional and longitudinal left ventricular systolic function.

In accordance with the dominant anterior location of STEMI in patients with LVSD, the culprit lesion was found much more frequently in the left descending artery in this subgroup than in patients without LVSD (Table 2). Furthermore, patients with LVEF ≤40 % at discharge presented with considerably less favourable pre-pPCI angiographic indices and interventional cardiologists were more likely to administer abciximab in this population than in patients with LVEF >40 % at discharge (Table 2). Although in the majority of patients pPCI resulted in a complete restoration of epicardial blood flow in the infarct-related artery, the incidence of complete reperfusion in the area of STEMI denoted by TMPG 3 was below 50 % in both subgroups.

Biomarkers

Patients with LVSD at discharge when compared to those with LVEF >40 % presented with a significantly higher maximal concentration of troponin I, markedly elevated plasma glucose on admission and noticeably increased white blood cell count at 24 h after admission (Table 2).

CRP plasma concentration rose steeply during the first 24 h of hospitalization (p < 0.001) and persisted elevated at discharge, mainly in patients with LVSD (Fig. 1). As shown in Figs. 2 and 3, the prevalence of LVSD was significantly increased across increasing tertiles of CRP concentration, both at 24 h after admission (cut-off values of ≤6.5 and >15.2 mg/L for the lower and upper tertile, respectively) and at discharge (cut-off values of <7.1 and >15.2 mg/L for the lower and upper tertile, respectively).
Table 2  Angiographic, echocardiographic and biochemical characteristics of study population

| Variable                                      | Overall study population (n = 204) | Patients with LVSD (n = 57) | Patients without LVSD (n = 147) | p for comparison between groups with and without LVSD |
|-----------------------------------------------|-----------------------------------|-----------------------------|---------------------------------|--------------------------------------------------------|
| **Angiographic indices**                      |                                   |                             |                                 |                                                        |
| IRA: LAD/non-LAD, n (%)                       | 93 (45.6)/111 (54.4)              | 52 (91.2)/5 (8.8)           | 41 (27.9)/106 (72.1)            | <0.001                                                 |
| Multivessel coronary artery disease, n (%)   | 123 (60.3)                        | 38 (66.7)                   | 85 (57.8)                       | NS                                                     |
| Stenosis in IRA in QCA (%)                   |                                   |                             |                                 |                                                        |
| Before pPCI                                   | 93.9 ± 9.5                        | 95.5 ± 9.2                  | 93.3 ± 9.5                      | 0.035                                                  |
| After pPCI                                    | 11.7 ± 10.1                       | 10.6 ± 8.2                  | 12.1 ± 10.7                     | NS                                                     |
| **Echocardiographic indices**                 |                                   |                             |                                 |                                                        |
| TFC in IRA (frames/s)                         |                                   |                             |                                 |                                                        |
| Before pPCI                                   | 74.6 ± 33.5                       | 83.1 ± 29.2                 | 71.3 ± 34.6                     | 0.021                                                  |
| After pPCI                                    | 25.8 ± 17.9                       | 28.0 ± 15.2                 | 24.9 ± 18.9                     | 0.017                                                  |
| **Biochemical parameters**                   |                                   |                             |                                 |                                                        |
| Creatinine (μmol/L)                           | 85.0 ± 15.7                       | 87.6 ± 16.7                 | 84.0 ± 15.2                     | NS                                                     |
| Admission glucose (mmol/L)                   | 8.46 ± 3.05                       | 9.77 ± 4.24                 | 7.96 ± 2.26                     | 0.002                                                  |
| HbA1c (%)                                     | 6.3 ± 1.1                         | 6.6 ± 1.4                   | 6.2 ± 1.0                       | NS                                                     |
| TnI_{max} (ng/mL)                             | 32.1 ± 19.6                       | 43.4 ± 14.3                 | 27.7 ± 19.7                     | <0.001                                                 |
| Ck-MB_{max} (U/L)                             | 120.5 ± 81.6                      | 158.1 ± 86.3                | 105.5 ± 74.8                    | <0.001                                                 |
| Leukocyte count at admission (10^3 per μL)   | 11.2 ± 3.0                        | 11.6 ± 2.8                  | 11.1 ± 3.0                      | NS                                                     |
| Leukocyte count 24 h after admission (10^3 per μL) | 10.3 ± 2.6                     | 11.5 ± 3.0                  | 9.9 ± 2.2                       | <0.001                                                 |
| BNP at admission (pg/mL)                     | 87.1 ± 140.0                      | 136.8 ± 230.4               | 67.9 ± 74.6                     | 0.002                                                  |
| BNP at discharge (pg/mL)                     | 205.0 ± 260.2                     | 401.0 ± 386.0               | 129.0 ± 127.0                   | <0.001                                                 |

Echocardiographic indices are derived from 2D and Doppler echocardiography and tissue Doppler echocardiography at hospital discharge.  
BNP, B-type natriuretic peptide,  CK-MB_{max}  maximal activity of isoenzyme MB of creatine kinase,  DES  drug-eluting stent,  IRA  infarct-related artery,  LA  left atrium;  LAD  left anterior descending artery,  LVEDd  left ventricular end-diastolic diameter,  LVEDVI  left ventricular end-diastolic volume index,  LVESd  left ventricular end-systolic diameter,  LVESVI  left ventricular end-systolic volume index;  LVMI  left ventricle mass index,  LVEDV  left ventricular end-diastolic volume,  LVEF  left ventricular ejection fraction,  pPCI  primary percutaneous coronary intervention,  TFC  TIMI frame count,  Thrombolysis in Myocardial Infarction score,  WMSI  wall motion score index.

BNP concentration increased during hospitalization in all patients (p < 0.001). However, its markedly higher values were observed in the group with LVEF ≤40% at both time points, allowing early identification of patients prone to developing global LVSD (Table 2).
Markers of LVSD in multivariate analysis

Markers of LVSD at discharge revealed by the univariate logistic regression analysis are presented in Table 3. The final model of multivariate logistic regression analysis found the anterior location of STEMI, maximal concentration of troponin I and CRP plasma concentration at discharge to be independent factors associated with early LVSD. Surprisingly, despite a very good ability to distinguish between patients with and without LVSD and an excellent discriminating value in the univariate analysis, BNP concentration failed to be an independent marker of LVSD in the multivariate analysis. Similarly, when adjusted for CRP concentration the leukocyte count was no longer associated with LVSD in the multivariate analysis.

Optimal cut-off values for the detection of LVSD

The ROC curve analysis assessing the diagnostic accuracy for the detection of LVSD at discharge revealed optimal cut-off values of 17.5 mg/L for CRP at discharge (sensitivity 49.1 %, specificity 83.7 %, positive value for LVSD detection 53.8 %, negative value for LVSD detection 80.9 %) and 46.3 ng/mL for maximal troponin I concentration (sensitivity 80.7 %, specificity 63.9 %, positive value for LVSD detection 46.5 %, negative value for LVSD detection 89.5 %). Areas under the ROC curves for CRP at discharge and the maximal troponin I concentration were 0.695 (95 % CI 0.627–0.757) and 0.779 (95 % CI 0.716–0.834), respectively. Comparison of the ROC curves for both biomarkers in terms of their diagnostic accuracy demonstrated the superiority of the maximal troponin I concentration over CRP value at discharge of a borderline significance (p = 0.06).

Determinants of CRP concentration

We applied the multiple regression model to determine which of the demographic, clinical, angiographic and biochemical parameters listed in Tables 1 and 2 affect CRP concentration at discharge. Increased BNP values at discharge, high maximal concentration of troponin I and elderly age were independently associated with elevated CRP concentration at discharge (Table 4).

Discussion

The main finding of our study is a clear relationship between in-hospital CRP plasma concentrations and the development of early post-infarct LVSD in patients...
undergoing pPCI for a first STEMI. In the homogeneous population treated in line with contemporary standards, CRP maintained its discriminating value for early post-infarct LVSD detection, even when adjusted for well-established clinical, biochemical and angiographic risk factors. Of interest, CRP concentration at discharge identified patients with early post-infarct LVSD better than leukocyte count and BNP concentration. When CRP value at discharge was incorporated into the multivariable model, both leukocyte count and BNP concentration lost their discriminating values.

The rapid rise in CRP concentration within 24 h of symptom onset persisting until discharge reflects the severity of the inflammatory reaction within the infarcted area. We found maximal concentration of troponin I, BNP value at discharge and patient’s age to be independent determinants of the magnitude of the inflammatory response assessed by CRP concentration at discharge.

We selected CRP as a sensitive, well-standardized biomarker with proven value in terms of clinical risk stratification in cardiovascular medicine. Increased CRP concentrations were linked with an excess risk of death.

Table 3  Markers of early left ventricular systolic dysfunction in univariate and multivariate analyses

| Univariate analysis | OR | 95 % CI   | p      |
|---------------------|----|----------|--------|
| Anterior vs. non-anterior wall STEMI | 30.92 | 11.41–83.75 | <0.0001 |
| Heart failure prior to MI (I or II class according to the NYHA classification) | 7.52 | 3.00–18.83 | <0.0002 |
| Body mass index (for a 10 kg/m² increase) | 2.76 | 1.22–6.23 | <0.02 |
| Hypertension | 2.11 | 1.13–3.95 | <0.02 |
| Diabetes mellitus | 2.03 | 0.96–4.29 | 0.066 |
| BNP at discharge (for a 100 pg/mL increase) | 1.89 | 1.48–2.43 | <0.0001 |
| TnImax (for a 10 ng/mL increase) | 1.67 | 1.35–2.06 | <0.0001 |
| BNP at admission (for a 100 pg/mL increase) | 1.61 | 1.14–2.28 | <0.01 |
| CRP 24 h after admission (for a 10 mg/L increase) | 1.60 | 1.27–2.00 | <0.0001 |
| CRP at discharge (for a 10 mg/L increase) | 1.55 | 1.24–1.93 | <0.0002 |
| Age (for a 10-year increase) | 1.38 | 0.99–1.94 | 0.056 |
| CRP at admission (for a 10 mg/L increase) | 1.37 | 0.27–7.03 | 0.70 |
| Leukocyte count 24 h after admission (for a 10³ per L increase) | 1.30 | 1.14–1.48 | <0.002 |
| HbA1c (for a 1 % increase) | 1.29 | 1.00–1.66 | <0.05 |
| Admission glycaemia (for a 1 mmol/L increase) | 1.21 | 1.08–1.35 | <0.001 |
| CK-MBmax (for a 10 U/L increase) | 1.08 | 1.04–1.13 | <0.0002 |
| Leukocyte count at admission (for a 10³ per L increase) | 1.06 | 0.96–1.18 | 0.25 |

Table 4  Impact of demographic, clinical, angiographic and biochemical variables from Tables 1 and 2 on CRP concentration at discharge in the multiple regression model

| Beta coefficient | Beta coefficient standard error | Direction component beta | Direction component beta standard error | p |
|------------------|-------------------------------|--------------------------|----------------------------------------|----|
| Intercept | -0.80 | 0.61 |
| Age (for a 10-year increase) | 0.15 | 0.06 | 0.24 | 0.10 | <0.02 |
| TnImax (for a 10 ng/mL increase) | 0.21 | 0.07 | 0.15 | 0.05 | <0.002 |
| BNP at discharge (for a 100 pg/mL increase) | 0.35 | 0.07 | 0.20 | 0.04 | <0.00001 |

CRP C-reactive protein, TnImax maximal concentration of troponin I
heart failure, cardiac rapture, ventricular aneurysmal formation, and thrombus formation in MI survivors [9–13, 20, 21]. Incorporation of CRP into the Global Registry of Acute Coronary Events risk score further improved its predictive power [14]. Therefore, combining these data with our results, we and other authors believe that CRP might be a simple and reliable marker for the magnitude of the inflammatory response to myocardial necrosis, providing prognostic information in STEMI patients [10, 22].

To the best of our knowledge, this is the first study linking CRP concentration and post-infarct LVSD conducted exclusively in a STEMI population, in a subset of patients with severely deteriorated epicardial blood flow and a large area of infarcted myocardium. Moreover, we applied strict inclusion criteria and numerous exclusion criteria to eliminate many of the potential confounders in our study. Almost three-quarters of our patients had an impaired TIMI flow on the initial angiogram while the median maximal concentration of troponin I in the study participants was 100-fold higher than the detection limit for MI in our laboratory. Previous studies in this field mostly recruited patients with a broad spectrum of acute coronary syndromes [23–25]. This fact seems to be of paramount importance when considering different mechanisms responsible for CRP synthesis as well as dissimilar magnitudes of CRP release in MI versus unstable angina [22, 26]. In stable and unstable coronary artery disease, elevated CRP reflects inflammation in the vascular bed or vulnerability of unstable plaques in contrast to MI, where the inflammatory response to myocardial necrosis dominates.

As far as we know a study conducted by Aggelopoulos et al. [23] is the only one to date investigating the relationship between CRP concentration and the presence of LVSD in patients treated for acute coronary syndromes. Other studies [24, 25, 27] in this field assessed LVEF as a continuous variable. Aggelopoulos et al. [23] showed that an increase in CRP plasma concentration during 12 h after admission as high as 10 mg/L was an independent predictor of a 6% augmentation of risk for LVSD at discharge. However, the results may be at least partially flawed by important limitations such as retrospective case-control design, history of coronary artery disease in almost half of the study participants, inclusion of patients with unstable angina, exclusion of patients with LVEF between 40 and 50% from the analysis and application of low-sensitivity CRP assay.

Studies linking CRP concentrations and LVEF in MI survivors gave conflicting results [8, 25, 28]. Örn et al. demonstrated that early measurement of CRP (viz. at 2 days and 1 week) significantly predicted LVEF assessed by cardiac magnetic resonance after 2 months in a small but well-designed study of STEMI patients [28]. Similarly, Uehara et al. [8] found a significant inverse correlation between the peak of in-hospital CRP concentration and LVEF at 1 month after STEMI. It is likely that various confounders present in many of the studies addressing this issue might lead to unreliable conclusions. For example, heterogeneity of the investigated population, with a substantial proportion of unstable angina patients, might have been the reason for the lack of correlation between CRP concentration and LVEF in the study by Brunetti et al. [25]. Furthermore, the timing of CRP assessment in the course of MI seems to be crucial for its diagnostic value. In our study, while absent on admission (with 4 h mean delay between symptom onset and admission), significantly higher CRP concentrations were present 24 h after admission and at discharge in patients with early LVSD. Corresponding to our results, Arruda-Olson et al. [24] observed comparable values of LVEF and WMSI in tertiles of CRP evaluated at a median of 6.1 h after symptom onset. On the other hand, Suleiman et al., who measured CRP 12–24 h after symptom onset, found inverse relations between CRP concentration and both LVEF and WMSI values in patients with acute MI [10].

Finally, it remains an unsolved issue whether CRP directly contributes to post-infarct LVSD and may be a potential therapeutic target, or if it just reflects an increased risk for unfavourable outcome as a bystander marker [29, 30]. A large body of basic scientific evidence suggests that CRP possesses both pronecrotic and proatherogenic features. Firstly, CRP binds to phosphocholine groups of necrotic myocardial cell membranes, leading to complement activation and thus promoting further inflammatory response, injury of myocardial cells and expansion of necrosis [31, 32]. Secondly, elevated endogenous CRP was associated with an increase in ischemia/reperfusion injury in a rabbit model [33]. Thirdly, increased C-reactive protein expression exacerbated LVSD and remodeling after MI in a mouse model [34]. This deleterious effect of CRP on post-MI left ventricular remodeling was related to increased apoptotic rates, macrophage infiltration, monocyte chemotactic protein-1 expression and matrix metalloproteinase-9 activity in the border zone. Additionally, CRP reduces bioavailability of nitric oxide, which in turn suppresses angiogenesis [35]. CRP also inhibits endothelial progenitor cell differentiation, function and survival [36].

Limitations of the study

Major limitations of our study include short-term follow-up and lack of concomitant assessment of cytokines and growth factors. Furthermore, due to early achievement of reperfusion, our patients had relatively well-preserved left ventricular systolic function. Additionally, we did not account in our calculations for diurnal and seasonal
variations in CRP concentration. Despite encouraging results obtained in our study, further efforts are warranted to confirm their clinical significance and to fully explain the mechanisms through which augmentation of the inflammatory process contributes to the occurrence of LVSD and subsequently to the development of heart failure following a STEMI.

Conclusions

The measurement of CRP plasma concentration at discharge may be useful as a marker of early LVSD in patients after a first STEMI.

Acknowledgments

This study was supported from the financial resources of The Polish Ministry of Science and Higher Education for science in years 2008–2011 (research project number N402179534) and by Servier Research Grant 2007 awarded in cooperation with the Polish Cardiac Society.

Conflict of interest

We have no conflict of interest in this study.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97(10A):13F–25F.
2. Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, O’Connor CM, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALLIANT Registry. Eur Heart J. 2004;25:1911–9.
3. Cleland JG, Torabi A, Khan NK. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart. 2005;91(Suppl 2):i7–13.
4. Kübler T, Gislason GH, Keber L, Torp-Pedersen C. Persistence of the prognostic importance of left ventricular systolic function and heart failure after myocardial infarction: 17-year follow-up of the TRACE register. Eur J Heart Fail. 2010;12:805–11.
5. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31–47.
6. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543–53.
7. Bouvini RF, Hendirt T, Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur Heart J. 2005;7(Suppl 1):I27–36.
8. Uehara K, Nomura M, Ozaki Y, Fujinaga H, Ikefuji H, Kimura M, et al. High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels. 2003;18:67–74.
9. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997;96:778–84.
10. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction—predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47:962–8.
11. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007;53:1800–7.
12. Smit JJ, Ottervanger JP, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoornjte JC, et al. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol. 2008;101:446–51.
13. Kruk M, Przyłuski J, Kaliniczuk Ł, Pregowski J, Deptuch T, Kadziela J, et al. Association of non-specific inflammatory activation with early mortality in patients with ST-elevation acute coronary syndrome treated with primary angioplasty. Circ J. 2008;72:205–11.
14. Schiele F, Meneveau N, Seronde MF, Chopard R, Descotes-Genon V, Dutheil J, et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J. 2010;31:290–7.
15. Möller JE, Brendorp B, Ottesen M, Køber L, Eegstrup K, Poulsen SH, et al. Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: clinical and prognostic implications. Eur J Heart Fail. 2003;5:811–9.
16. Rott D, Behar S, Hod H, Feinberg MS, Boyko V, Mandelzweig L, et al. Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures. Am Heart J. 2001;141:267–76.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–67.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79–108.
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.
20. Widmer A, Linka AZ, Attenhofer Jost CH, Buergi B, Brunner-La Rocca HP, Salomon F, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99:25–31.
21. Anzai T, Yoshikawa T, Kaneko H, Maekawa Y, Iwanaga S, Asakura Y, et al. Association between serum C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99:25–31.
22. Zebrack JS, Anderson JL. Should C-reactive protein be measured routinely during acute myocardial infarction? Am J Med. 2003;115:735–7.
23. Aggelopoulos P, Chrysohooou C, Pitsavos C, Papadimitriou L, Lioutou C, Panagiotakos D, et al. Comparative value of simple inflammatory markers in the prediction of left ventricular systolic dysfunction in postacute coronary syndrome patients. Mediators Inflamm. 2009;2009:826297.
24. Arruda-Olson AM, Enriquez-Sarano M, Bursi F, Weston SA, Jaffe AS, Killian JM, et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol. 2010;105:917–21.
25. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome:
correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006;109:248–56.
26. James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J. 2005;149:619–26.
27. Ohlmann P, Jaquemin L, Morel O, El Behlgiti R, Faure A, Michotey MO, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for STElevation myocardial infarction. Am Heart J. 2006;152:1161–7.
28. Ørn S, Manhenke C, Ueland T, Damås JK, Mollnes TE, Edwardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J. 2009;30:1180–6.
29. Kitsis R, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med. 2006;355:513–5.
30. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217–21.
31. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97–103.
32. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733–40.
33. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303:1007–13.
34. Takahashi T, Anzai T, Kaneko H, Mano Y, Anzai A, Nagai T, et al. Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2010;299:H1795–804.
35. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–9.
36. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109:2058–67.